A novel 5’ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma

With the development of next generation sequencing(NGS), more and more novel ALK fusion partners have been reported since the discovery of anaplastic lymphoma kinase fusion-positive (ALK+) NSCLC (EML4-ALK) in 2007 [1]. The pace that new fusion partners are being identified and reported has rapidly increased since 2018. According to the report, distinct 5’ fusion partners identified in ALK + NSCLC are up to 90 by the end of January 2020 [2]. However the need to identify rare actionable driver mutations are still urgent and unmet.